Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms

[1]  J. Verweij,et al.  Clinical Pharmacokinetics of Docetaxel , 2006, Clinical pharmacokinetics.

[2]  M. Haberl,et al.  Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations , 2006, Pharmacogenetics and genomics.

[3]  Lewis B. Sheiner,et al.  A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[4]  D. Greenblatt,et al.  Genotype‐phenotype Associations of Cytochrome P450 3A4 and 3A5 Polymorphism with Midazolam Clearance in Vivo , 2005, Clinical pharmacology and therapeutics.

[5]  G. Hortobagyi,et al.  Docetaxel for treatment of solid tumours: a systematic review of clinical data. , 2005, The Lancet. Oncology.

[6]  P. Beaune,et al.  Consequences of Genetic Polymorphisms for Sirolimus Requirements After Renal Transplant in Patients on Primary Sirolimus Therapy , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  Shinzaburo Noguchi,et al.  Prediction of docetaxel response in human breast cancer by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Verweij,et al.  Relationship of Systemic Exposure to Unbound Docetaxel and Neutropenia , 2005, Clinical pharmacology and therapeutics.

[9]  T. Rebbeck,et al.  CYP3A4, CYP3A5, and CYP3A43 Genotypes and Haplotypes in the Etiology and Severity of Prostate Cancer , 2004, Cancer Research.

[10]  Yingjin Yuan,et al.  Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. , 2004, Cancer letters.

[11]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[12]  C. Verlinde,et al.  Characterization of atrazine biotransformation by human and murine glutathione S-transferases. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[13]  F. Dalenc,et al.  Dexamethasone as a probe for docetaxel clearance , 2004, Cancer Chemotherapy and Pharmacology.

[14]  C. Flamant,et al.  Glutathione-S-transferase M1, M3, P1 and T1 polymorphisms and severity of lung disease in children with cystic fibrosis. , 2004, Pharmacogenetics.

[15]  A. Telenti,et al.  Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects , 2004, European Journal of Clinical Pharmacology.

[16]  T. Rebbeck,et al.  CYP 3 A 4 , CYP 3 A 5 , and CYP 3 A 43 Genotypes and Haplotypes in the Etiology and Severity of Prostate Cancer , 2004 .

[17]  H. Dienemann,et al.  The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. , 2003, Pharmacogenetics.

[18]  W. Weimar,et al.  Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus , 2003, Clinical pharmacology and therapeutics.

[19]  Ji-yao Wang,et al.  Docetaxel inhibits SMMC-7721 human hepatocellular carcinoma cells growth and induces apoptosis. , 2003, World journal of gastroenterology.

[20]  M. Spitz,et al.  Association between glutathione S-transferase p1 polymorphisms and lung cancer risk in Caucasians: a case-control study. , 2003, Lung cancer.

[21]  T. Rebbeck,et al.  Increased transcriptional activity of the CYP3A4*1B promoter variant , 2003, Environmental and molecular mutagenesis.

[22]  F. Ali-Osman,et al.  Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. , 2002, Pharmacogenetics.

[23]  B. Goh,et al.  Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Giles,et al.  The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. , 2002, Pharmacogenetics.

[25]  K. Tanimoto,et al.  Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers. , 2002, International Journal of Oncology.

[26]  Jacques Fellay,et al.  Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.

[27]  L. Hutchins,et al.  Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. , 2001, Cancer research.

[28]  M. Fromm,et al.  The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. , 2001, Pharmacogenetics.

[29]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[30]  C. Meisel,et al.  Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects , 2001, Clinical pharmacology and therapeutics.

[31]  C. Veyrat‐Follet,et al.  Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization , 2000, Clinical pharmacology and therapeutics.

[32]  S. Ackland,et al.  Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[33]  J. Hayes,et al.  Glutathione S-Transferase Polymorphisms and Their Biological Consequences , 2000, Pharmacology.

[34]  S. Clark,et al.  A Distinct Sequence (ATAAA) n Separates Methylated and Unmethylated Domains at the 5′-End of theGSTP1 CpG Island*210 , 2000, The Journal of Biological Chemistry.

[35]  J. Verweij,et al.  Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  N. Saijo,et al.  Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Watkins,et al.  The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  J. Verweij,et al.  The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Bowen,et al.  Glutathione S-transferase enzyme expression in hematopoietic cell lines implies a differential protective role for T1 and A1 isoenzymes in erythroid and for M1 in lymphoid lineages. , 2000, Haematologica.

[41]  P. Hopkins,et al.  Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4 , 1999, Clinical pharmacology and therapeutics.

[42]  L. Rivory,et al.  Clinical Pharmacokinetics of Docetaxel , 1999, Clinical pharmacokinetics.

[43]  K. Korzekwa,et al.  Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. , 1998, Pharmacogenetics.

[44]  G. B. Smith,et al.  Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. , 1998, Carcinogenesis.

[45]  L B Sheiner,et al.  Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Verweij,et al.  Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  D. Forman,et al.  Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. , 1997, Carcinogenesis.

[48]  J. Buolamwini,et al.  Molecular Cloning, Characterization, and Expression in Escherichia coli of Full-length cDNAs of Three Human Glutathione S -Transferase Pi Gene Variants EVIDENCE FOR DIFFERENTIAL CATALYTIC ACTIVITY OF THE ENCODED PROTEINS* , 1997 .

[49]  J. Beijnen,et al.  Isolation, purification and biological activity of major docetaxel metabolites from human feces. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[50]  I. Roninson,et al.  Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells , 1991, Cell.

[51]  T. Triche,et al.  An immunohistochemical study of pi class glutathione S-transferase expression in normal human tissue. , 1990, The American journal of pathology.

[52]  A Schumitzky,et al.  A program package for simulation and parameter estimation in pharmacokinetic systems. , 1979, Computer programs in biomedicine.